A Phase II Study Exploring the Safety and Efficacy of Nintedanib (BIBF1120) as Second Line Therapy for Patients With Either Differentiated or Medullary Thyroid Cancer Progressing After First Line Therapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Nintedanib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 23 Feb 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jul 2018.
- 23 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Jul 2016 Planned primary completion date changed from 1 May 2016 to 1 Jan 2018.